Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
By Justice Department, Drug Enforcement Administration · Oct 8, 2026, 11:00 PM CDT
On August 12, 2026, the Drug Enforcement Administration (DEA) published a temporary order placing O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Ac
Excerpt shown under fair-use limits. Full text remains with the original publisher.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisFramingThe article frames the correction as fixing an inadvertent omission, emphasizing procedural accuracy rather than policy controversy.
LanguageUse of the word "inadvertently" suggests a neutral, non‑malicious error, which downplays any potential criticism of the original order.
Context
AI analysisMissing context
The article does not explain why O-desmethyltramadol was placed in Schedule I, what the public health or regulatory implications are, or any background on the substance’s abuse potential or medical use. It also lacks information about the process for issuing temporary orders and corrections, and any reactions from stakeholders.
Important context
Understanding the DEA’s authority to place substances in Schedule I, the criteria used for such scheduling, and the potential impact on medical providers, patients, and law enforcement would provide essential context for this announcement.
Opinion vs. reporting
AI analysisThe piece is primarily factual reporting of an official action and a correction; it does not contain overt opinion or editorial commentary.